By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


HedgePath Pharmaceuticals 

324 S. Hyde Park Avenue
Suite #350
Tampa  Florida  33606  U.S.A.
Phone: 813-864-2560 Fax: 813-527-0500


Company News
HedgePath Pharmaceuticals Announces Positive Interim Data In Its Phase II(B) Cancer Trial 8/3/2016 6:34:02 AM
HedgePath Pharmaceuticals Release: FDA Grants Orphan Drug Designation to SUBA-Itraconazole For Treatment Of Patients With BCCNS 6/2/2016 7:15:20 AM
HedgePath Pharmaceuticals Announces Completion Of $5.5 Million Private Placement Offering 6/1/2016 8:48:16 AM
HedgePath Pharmaceuticals Announces Commencement Of Patient Treatment In Its Phase II(b) Clinical Trial 9/29/2015 6:31:10 AM
HedgePath Pharmaceuticals Launches Clinical Trial For Its Proposed Cancer Treatment 8/21/2015 6:27:25 AM
HedgePath Pharmaceuticals To Receive $2.5 Million in Funding From Mayne Pharma 5/18/2015 7:37:53 AM
HedgePath Pharmaceuticals Receives IND Clearance To Commence Development Of Its Proposed Cancer Treatment 12/16/2014 9:02:25 AM
HedgePath Pharmaceuticals Files IND Application 11/18/2014 12:10:50 PM
HedgePath Pharmaceuticals Welcomes Three New Board Members 6/26/2014 9:38:50 AM
HedgePath Pharmaceuticals Secures Interim Financing To Commence Clinical Trials And Finalizes Key Agreement With Mayne Pharma Limited 6/25/2014 7:50:20 AM